BN and JB declare no conflict of interest. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. AZD6738 ic50 HIV Med. 2012;13(Suppl 2):1–85. 2. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J,

Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at

48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60(1):33–42.PubMedCrossRef 3. Nelson Tanespimycin M, Girard PM, Demasi R, Chen L, Smets E, Sekar V, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother. 2010;65(7):1505–9.PubMedCrossRef 4. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57–65.PubMedCrossRef 5. Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, Liu HC, et al. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to selleck inhibitor tenofovir DF/emtricitabine, each with efavirenz. AIDS Care. 2011;23(6):705–13.PubMedCrossRef 6. Duran

S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2(1):38–45. 7. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination. Lancet. 2009;374(9692):796–806.PubMedCrossRef 8. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based. JAMA. 2011;305(13):1327–35.PubMedCentralPubMedCrossRef 9. Gianotti N, Tiberi S, Menzo S, Danise A, Boeri E, Galli L, et al. HIV-1 replication capacity and genotype changes in patients undergoing treatment. J Med Virol. 2008;80(2):201–8.PubMedCrossRef 10. Mathias AA, Germa P, Lee M, et al.